Table 3.
Summary of results—incidence of brain metastases and survival—extracted from the trials on NSCLC included in this systematic review and meta-analysis (PCI versus no PCI).
| Brain metastases (%) | Median survival (months)/overall survival % at [X year(s)] | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Primary (cure-intended) therapy | Stage | PCI dose | N | PCI | Control | p-Value | PCI | Control | p-Value |
| Cox et al. (30) | RT only | Inoperable | 20 (2 Gy × 10) | 281 | 7/136 (6%) | 16/145 (13%) | 0.038 | 8.2 months | 9.7 months | 0.5 |
| Umsawasdi et al. (31) | Triple modality (surgery + RT + CT) | I–II (13%) III (87%) |
30 (3 Gy × 10) | 97 | 2/46 (4%) | 14/51 (27%) | 0.002 | 22% (3 years) | 23.5% (3 years) | Not reported |
| Russell et al. (32) | RT only | I/III | 30 (3 Gy × 10) | 187 | 8/93 (9%) | 18/94 (19%) | 0.1 | 8.4 months 40% (1 year) 13% (2 years) |
8.1 months 44% (1 year) 21% (2 years) |
0.36 |
| Miller et al. (33) | RT + CT | III | 30 (2 Gy × 15) 37.5 (2.5 Gy × 15) |
226 | 1/111 (1%) | 13/115 (11%) | 0.003 | 8 months | 11 months | 0.004 |
| Gore et al. (49) [2012 abstract (50)] | Triple modality (surgery + RT + CT) | IIIA (54%) IIIB (46%) |
30 (2 Gy × 15) | 340 | 19/163 (17.3%) | 39/177 (26.8%) | 0.009 | 75.6% (1 year) 26.1% (5 years) |
76.9% (1 year) 24.6% (5 years) |
0.57 |
| Li et al. (52) | Surgery + CT | IIIA-N2 | 30 (3 Gy × 10) | 156 | 10/81 (12%) | 29/75 (39%) | <0.001 | 31.2 months 44.5% (3 years) 27.4% (5 years) |
27.4 months 38.7% (3 years) 22.8% (5 years) |
0.310 |
NSCLC, non-small cell lung cancer; PCI, prophylactic cranial irradiation; RT: radiation therapy; Gy: Gray; CT: chemotherapy.